News

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
Nasdaq1d
Regeneron and Sanofi Announce Dupixent Outperformance over Xolair in Phase 4 EVEREST Trial Results for CRSwNP and Asthma
Dupixent demonstrated superior efficacy in ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial ...
The Pharma Letter20h
Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis
French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...
Clinical Trials Arena on MSN6d
Regeneron and Sanofi’s dupilumab shows promise in AD trial
Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).
Yahoo Finance1d
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever ...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results ...
BioSpace7d
Sanofi, Regeneron Tout Dupixent’s Effectiveness in Patients With Darker Skin Tone
Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...
Seeking Alpha1d
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever ...
About Dupixent Dupixent, which was invented using Regeneron’s proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4 ...